Covid 19 Drug

More states announce lockdown as India sees record 4,187 COVID1-9 deaths, over 4 lakh cases in 24 hrs

The DCGI approved a new drug 2-deoxy-D-glucose (2-DG) developed by the DRDO as adjunct therapy. The defence ministry claimed the drug helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence

Researchers find new protein 41B that can be used as a drug target for COVID-19 treatment

Researchers also found about 127 other shared molecules between SARS-CoV-2 and other coronaviruses that were involved in various biological processes ranging from cell to cell communication metabolic processes going on inside the cell and cell growth

New antiviral oral drug molnupiravir completely suppresses coronavirus transmission within 24 hours in ferrets, claims study

Researchers claim that MK-4482/EIDD-2801 or molnupiravir is the first orally available drug to quickly block SARS-CoV-2 and has the potential of being ground-breaking

Anti-depressant drug fluvoxamine may help prevent severe COVID-19, suggests study

Previous research has shown that this drug can reduce inflammation and sepsis in animals by blocking IL-6, a pro-inflammatory cytokine. Unregulated inflammation and cytokine storms are possible causes of mortality in severe COVID-19 patients

Heartburn drug famotidine may reduce symptoms of non-hospitalised COVID-19 patients, suggests case series

A new drug, famotidine, available over-the-counter for relieving heartburn, has shown promising results in treating the symptoms of COVID-19

Strides Pharma receives regulatory approval to conduct trials in India for potential COVID-19 drug

Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has got regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19

India's Jubilant Life inks licensing agreement with Gilead to manufacture Remdesivir, a potential drug to treat COVID-19

Jubilant Life Sciences Ltd on Tuesday said it has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc that will grant it the right to register, manufacture and sell the latter's investigational drug, remdesivir